Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02025023
Other study ID # STUDY00003748
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date December 2013
Est. completion date July 2026

Study information

Verified date February 2020
Source University of Washington
Contact Simona Vuletic
Phone 206-520-9728
Email simona@uw.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Local injection of 5-fluorouracil into a chalazion (stye) is as effective as local injection of triamcinolone (steroid) and incision and curettage for treatment of chalazia.


Description:

This is a prospective randomized interventional study comparing four current standard-of-care treatments for chalazia: incision and curettage, local injection of triamcinolone, local injection of 5-FU, and local injection of combination triamcinolone/5-FU.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date July 2026
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Single or multiple chalazia in a single eyelid

Exclusion Criteria:

- Chalazia present for less than one month and no previous injection or incision and curettage

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
5-fluorouracil Injection
If the chalazion is present at follow-up visit, another injection of 5-FU will be given.
Triamcinolone Acetonide
If chalazion present at follow-up, another Triamcinolone injection will be done.
Procedure:
Incision and Curettage
If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.
Drug:
Triamcinolone Acetonide/5-fluorouracil mixture
If chalazion persists at follow-up visit, another injection of triamcinolone/5-FU mixture will be done.

Locations

Country Name City State
United States University of Washington Eye Institute at Harborview Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
University of Washington

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Size of chalazion 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT01202747 - Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction Phase 2/Phase 3
Completed NCT02338648 - Safety and Efficacy Study of SUN 131 TDS as Compared to Placebo TDS in Adult Patients With a Chalazion Phase 2
Completed NCT00420628 - Pediatric Zylet Safety and Efficacy Study Phase 4
Withdrawn NCT01763437 - Intralesional Tetracycline Injection in the Treatment of Chalazia Phase 0
Completed NCT03248440 - Safety and Efficacy Study of SUN-131 Transdermal System (TDS) as Compared to Placebo TDS in Patients With a Chalazion Phase 3
Recruiting NCT05070611 - Efficacy of Intense Pulsed Light in the Treatment of Recurrent Chalazia N/A
Completed NCT00832130 - Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye N/A
Completed NCT04322500 - Probiotics for Chalaziosis Treatment in Children N/A
Completed NCT04342507 - Probiotics for Treatment of Chalazion in Adults N/A
Recruiting NCT05512572 - Therapeutic Efficacy of Intense Pulsed Light in the Treatment of Chalazion N/A